Oncology & Cancer

Researchers identify potential formula for blood cancer vaccine

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma, a blood cancer, according to a study ...

Medications

New cancer inhibitor effective where others fail

A novel agent called Selinexor has opened up new options for the treatment of patients with refractory myeloma. This was the conclusion of a major international clinical trial in which also the Karl Landsteiner University ...

Oncology & Cancer

Lenalidomide may delay onset of myeloma-related bone, organ damage

The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage. Results of the study, which ...

Oncology & Cancer

Patient preferences explored in multiple myeloma treatment

(HealthDay)—An Eastern Cooperative Oncology Group (ECOG) performance status of ≥2 is linked to lower treatment satisfaction in patients with relapsed or refractory multiple myeloma (RRMM), but receiving medication orally ...

Oncology & Cancer

MGUS can progress to multiple myeloma within five years

(HealthDay)—Individuals with low- or intermediate-risk monoclonal gammopathy of undetermined significance (MGUS) can experience progression to multiple myeloma within five years, according to a study published online July ...

page 1 from 23